NRX Pharmaceuticals (NRXP) EBIT Margin (2025 - 2026)

NRX Pharmaceuticals (NRXP) posted quarterly EBIT Margin of 444.01% for Q1 2026, up 8.01% quarter-over-quarter from 482.67% in Q4 2025.

NRX Pharmaceuticals (NRXP) EBIT Margin (2025 - 2026) Analysis & Trends

NRX Pharmaceuticals (NRXP) has reported EBIT Margin for 2 consecutive years, with 444.01% the latest figure, recorded in Q1 2026.

In Q1 2026, EBIT Margin changed N/A year-over-year to 444.01%; the TTM figure through Mar 2026 stood at 769.09% (changed N/A YoY), while the FY2025 annual figure was 1352.0%, changed N/A from the prior year.
EBIT Margin grew to 444.01% in Q1 2026 per NRXP's latest filing, from 482.67% in the prior quarter.
Across five years, EBIT Margin topped out at 444.01% in Q1 2026 and bottomed at 2012.0% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Vertex Pharmaceuticals	138.83 Bn	130.98 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	85.79 Bn	77.79 Bn	3.93 Bn	30.15%
3	Argenx Se	64.95 Bn	59.77 Bn	1.37 Bn	32.54%
4	Moderna	58.59 Bn	53.46 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.93 Bn	36.83 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	31.52 Bn	28.21 Bn	992.69 Mn	17.93%
7	BioNTech SE	27.98 Bn	9.58 Bn	668.28 Mn	-35.57%
8	Insmed	27.42 Bn	26.26 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	27.33 Bn	26.49 Bn	-	19.75%
10	NRX Pharmaceuticals	132.53 Mn	105.83 Mn	426,000.00	-590.83%

Download Data